Our Origins

HaemaLogiX was formed to continue the development and commercialisation of a new Mab therapy to treat multiple myeloma. On 4 March 2015 HaemaLogiX purchased the main assets of Immune System Therapeutics Ltd (IST), a biotechnology company that was placed into liquidation.

IST operated for 13 years and was previously called Pacmab Limited. Mab technology is based on over 10 years of research conducted by Dr Rosanne Dunn at the University of Technology, Sydney. Dr Dunn now heads HaemaLogiX's Research and Clinical Development program.